Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.74 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090977 | 0.86 | VCAM1 (0.91) | VCAM1XDHCYP19A1GRIN2DGRIN3B | |
| SCHEMBL1005421 | 0.86 | VCAM1 (1.00) | VCAM1XDHCYP19A1GRIN2DGRIN3B | |
| SCHEMBL25409187 | 0.82 | VCAM1 (0.59) | VCAM1MEN1KMT2A | |
| SCHEMBL30508469 | 0.82 | VCAM1 (0.59) | VCAM1MEN1KMT2A | |
| SCHEMBL27088384 | 0.81 | VCAM1 (0.47) | VCAM1MEN1KMT2ACYP19A1TSHR | |
| Acetonitrile SCHEMBL27788615 | 0.80 | VCAM1 (0.88) | VCAM1XDHMEN1KMT2ACYP19A1 | |
| SCHEMBL7203812 | 0.79 | CYP19A1 (0.62) | VCAM1MEN1KMT2ACYP19A1TSHR | |
| SCHEMBL1172437 | 0.79 | CYP19A1 (0.55) | VCAM1MEN1KMT2ACYP19A1TSHR | |
| SCHEMBL1344128 | 0.77 | VCAM1 (0.74) | VCAM1XDHMEN1KMT2ACYP19A1 | |
| SCHEMBL3771130 | 0.77 | VCAM1 (0.74) | VCAM1XDHCYP19A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349018-B | Process for fluorinating inorganic or organic compounds by direct fluorination | 福建永晶科技股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117209472-A | KIF18A inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2023-10-24 | — | — | US | disclosed |
| CN-116903589-A | KIF18A inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11447446-B2 | Process of fluorinating inorganic or organic compounds by direct fluorination | FUJIAN YONGJING TECHNOLOGY CO., LTD (CN) | 2022-09-20 | — | — | US | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | Fujian Yongjing Technology Co.,Ltd (CN) | 2022-05-05 | — | — | US | disclosed |
| WO-2007070626-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1713791-A1 | 5-FLUORO-, CHLORO- AND CYANO-PYRIDIN-2-YL-TETRAZOLES AS LIGANDS OF THE METABOTROPIC GLUTAMATE RECEPTOR-5 | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005066155-A1 | 5-FLUORO-, CHLORO- AND CYANO-PYRIDIN-2-YL-TETRAZOLES AS LIGANDS OF THE METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-6552018-B1 | As antitumor agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| CN-1105707-C | Pyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2003-04-16 | — | — | CN | disclosed |
| US-6169086-B1 | AN ANTITUMOR AGENT FOR TREATING TUMOR RESISTANT TO 5-FLUOROURACIL TYPE DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-1022270-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| CN-1251578-A | Pyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2000-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795138-B2 | Process of fluorinating inorganic compounds by direct fluorination | AFF2, CYP4F2, AFF1 | VCAM1 4730/4885XDH 1467/4885MEN1 1377/4885 |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | VCAM1 3142/4885XDH 369/4885MEN1 4344/4885 |
| US-20220135516-A1 | Process of Fluorinating Inorganic Compounds by Direct Fluorination | AFF2, CYP4F2, AFF1 | VCAM1 4730/4885XDH 1467/4885MEN1 1377/4885 |
| US-11447446-B2 | Process of fluorinating inorganic or organic compounds by direct fluorination | CYP4F2, AFF2, CYP4F3 | VCAM1 4745/4885XDH 1381/4885MEN1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.